Søren Blindbæk - Aflibercept anD navigateD vErsus coNvensional laser in Diabetic macUlar edeMa (ADDENDUM)

Diabetic macular edema (DME) in diabetic retinopathy (DR) is the leading cause of visual impairment among the 300,000 Danish patients with diabetes (DM) and will in time affect 29% of patients. Because of DME, 550 intravitreal injections were given at Odense University Hospital in 2014 with medicine expenses approximating 3.3 million DKK.

With an increasing prevalence of diabetes, the number is expected to rise significantly for the years to come. We hypothesize that combination therapy with intravitreal aflibercept and a new computer navigated photocoagulations system (Navilas®) leads to a decreased need for intravitreal injections.

Further, we wish to identify retinal risk markers for DME treatment outcome to assist individualized treatment planning.
The ADDENDUM study (four-year part-time PhD study) is a 12-moth prospective randomized 1:1 study to compare intravitreal aflibercept and Navilas® laser (Group A) with intravitreal aflibercept and conventional Pascal laser (Group B) in the treatment of DME.

Eligibility criteria: DM, age 18-99, clinically significant macular edema, central retinal thickness > 300 μm, best corrected visual acuity 35-75 ETDRS letters.

We believe that this study holds the potential to set precedent for a new gold standard of DME-treatment with increased treatment effect, reduced risks and a more cost-effective approach.